Targeting fundamental aging mechanisms to treat osteoporosis

References

• Kanis JA, Melton III LJ, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9(8):1137–1141.
   PubMed Web of Science ®Google Scholar
• Harvey N, Dennison E, Cooper C. Osteoporosis: impact on health and economics. Nat Rev Rheumatol. 2010 Feb;6(2):99–105.
   PubMed Web of Science ®Google Scholar
• Woo S-B, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jawsbisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144(10):753–761.
   PubMed Web of Science ®Google Scholar
• Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011;364(18):1728–1737.
   PubMed Web of Science ®Google Scholar
• Langdahl B, Ferrari S, Dempster DW. Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis. Ther Adv Musculoskelet Dis. 2016;8(6):225–235.
   PubMed Web of Science ®Google Scholar
• Silva BC, Bilezikian JP. Parathyroid hormone: anabolic and catabolic actions on the skeleton. Curr Opin Pharmacol. 2015 Jun;22:41–50.
   PubMed Web of Science ®Google Scholar
• Guo J, Liu M, Yang D, et al. Phospholipase C signaling via the parathyroid hormone (PTH)/PTH-related peptide receptor is essential for normal bone responses to PTH. Endocrinology. 2010 Aug;151(8):3502–3513.
   PubMed Web of Science ®Google Scholar
• Tabacco G, Bilezikian JP. Osteoanabolic and dual action drugs. Br J Clin Pharmacol. 2019 Jun;85(6):1084–1094.
   PubMed Web of Science ®Google Scholar
• Yavropoulou MP, Michopoulos A, Yovos JG. PTH and PTHR1 in osteocytes. New insights into old partners. Hormones (Athens). 2017 Apr;16(2):150–160.
   PubMedGoogle Scholar
• Subbiah V, Madsen VS, Raymond AK, et al. Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int. 2010 Jun;21(6):1041–1045.
   PubMed Web of Science ®Google Scholar
• Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol Pathol. 2002 May -Jun;30(3):312–321.
   PubMed Web of Science ®Google Scholar
• Drake MT, Srinivasan B, Modder UI, et al. Effects of intermittent parathyroid hormone treatment on osteoprogenitor cells in postmenopausal women. Bone. 2011 Sep;49(3):349–355.
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001 May 10;344(19):1434–1441.
   PubMed Web of Science ®Google Scholar
• Cosman F, Lane NE, Bolognese MA, et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2010 Jan;95(1):151–158.
   PubMed Web of Science ®Google Scholar
• Shoyele SA, Sivadas N, Cryan SA. The effects of excipients and particle engineering on the biophysical stability and aerosol performance of parathyroid hormone (1–34) prepared as a dry powder for inhalation. AAPS PharmSciTech. 2011 Mar;12(1):304–311.
   PubMed Web of Science ®Google Scholar
• Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001 Nov 16;107(4):513–523.
   PubMed Web of Science ®Google Scholar
• MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009 Jul;17(1):9–26.
   PubMed Web of Science ®Google Scholar
• Glass DA 2nd, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005 May;8(5):751–764.
   PubMed Web of Science ®Google Scholar
• Cui Y, Niziolek PJ, MacDonald BT, et al. Lrp5 functions in bone to regulate bone mass. Nat Med. 2011 Jun;17(6):684–691.
   PubMed Web of Science ®Google Scholar
• Holmen SL, Zylstra CR, Mukherjee A, et al. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem. 2005 Jun 3;280(22):21162–21168.
   PubMed Web of Science ®Google Scholar
• Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006 Nov 3;127(3):469–480.
   PubMed Web of Science ®Google Scholar
• Florio M, Gunasekaran K, Stolina M, et al. A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. Nat Commun. 2016;7:11505.
   PubMed Web of Science ®Google Scholar
• Kansara M, Tsang M, Kodjabachian L, et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest. 2009 Apr;119(4):837–851.
   PubMed Web of Science ®Google Scholar
• Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002 May 16;346(20):1513–1521.
   PubMed Web of Science ®Google Scholar
• Zhu M, Liu C, Li S, et al. Sclerostin induced tumor growth, bone metastasis and osteolysis in breast cancer. Sci Rep. 2017;7(1):11399.
   PubMedGoogle Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Reduced relative risk of fractures among users of lithium. Calcif Tissue Int. 2005 Jul;77(1):1–8.
   PubMed Web of Science ®Google Scholar
• Yao W, Cheng Z, Shahnazari M, et al. Overexpression of secreted frizzled-related protein 1 inhibits bone formation and attenuates parathyroid hormone bone anabolic effects. J Bone Miner Res. 2010 Feb;25(2):190–199.
   PubMed Web of Science ®Google Scholar
• Cho HY, Choi HJ, Sun HJ, et al. Transgenic mice overexpressing secreted frizzled-related proteins (sFRP)4 under the control of serum amyloid P promoter exhibit low bone mass but did not result in disturbed phosphate homeostasis. Bone. 2010 Aug;47(2):263–271.
   PubMed Web of Science ®Google Scholar
• Clement-Lacroix P, Ai M, Morvan F, et al. Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17406–17411.
   PubMed Web of Science ®Google Scholar
• Misztal K, Brozko N, Nagalski A, et al. TCF7L2 mediates the cellular and behavioral response to chronic lithium treatment in animal models. Neuropharmacology. 2017 Feb;113(Pt A):490–501.
   PubMedGoogle Scholar
• Ishimoto K, Hayano S, Yanagita T, et al. Topical application of lithium chloride on the pulp induces dentin regeneration. PloS One. 2015;10(3):e0121938.
   PubMed Web of Science ®Google Scholar
• Zamani A, Omrani GR, Nasab MM. Lithium’s effect on bone mineral density. Bone. 2009 Feb;44(2):331–334.
   PubMedGoogle Scholar
• Wang FS, Ko JY, Weng LH, et al. Inhibition of glycogen synthase kinase-3beta attenuates glucocorticoid-induced bone loss. Life Sci. 2009 Nov 4;85(19–20):685–692.
   PubMed Web of Science ®Google Scholar
• Refaey ME, McGee-Lawrence ME, Fulzele S, et al. Kynurenine, a tryptophan metabolite that accumulates with age, induces bone loss. J Bone Miner Res. 2017 Nov;32(11):2182–2193.
   PubMed Web of Science ®Google Scholar
• Vidal C, Li W, Santner-Nanan B, et al. The kynurenine pathway of tryptophan degradation is activated during osteoblastogenesis. Stem Cells. 2015 Jan;33(1):111–121.
   PubMed Web of Science ®Google Scholar
• Bozec A, Zaiss MM, Kagwiria R, et al. T cell costimulation molecules CD80/86 inhibit osteoclast differentiation by inducing the IDO/tryptophan pathway. Sci Transl Med. 2014 May 7;6(235):235ra60.
   PubMed Web of Science ®Google Scholar
• Kim B-J, Hamrick MW, Yoo HJ, et al. The detrimental effects of kynurenine, a tryptophan metabolite, on human bone metabolism. J Clin Endocrinol Metab. 2019;104:2334–2342.
   Web of Science ®Google Scholar
• Baban B, Chandler P, McCool D, et al. Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J Reprod Immunol. 2004 Apr;61(2):67–77.
   PubMed Web of Science ®Google Scholar
• Rosen CJ, Bouxsein ML. Mechanisms of Disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol. 2006 Jan 01;2(1):35–43.
   PubMedGoogle Scholar
• Duque G. Bone and fat connection in aging bone. Curr Opin Rheumatol. 2008;20(4):429–434.
   PubMed Web of Science ®Google Scholar
• Pino AM, Rosen CJ, Rodríguez JP. In osteoporosis, differentiation of mesenchymal stem cells (MSCs) improves bone marrow adipogenesis. Biol Res. 2012;45(3):279–287.
   PubMed Web of Science ®Google Scholar
• Singh L, Brennan TA, Russell E, et al. Aging alters bone-fat reciprocity by shifting in vivo mesenchymal precursor cell fate towards an adipogenic lineage. Bone. 2016;85:29–36.
   PubMed Web of Science ®Google Scholar
• Ganguly P, El-Jawhari JJ, Giannoudis PV, et al. Age-related changes in bone marrow mesenchymal stromal cells: a potential impact on osteoporosis and osteoarthritis development. Cell Transplant. 2017 Sep;26(9):1520–1529.
   PubMed Web of Science ®Google Scholar
• Al Saedi A, Hassan EB, Duque G. The diagnostic role of fat in osteosarcopenia. J Lab Precis Med. 2019;4:7.
   Google Scholar
• Elbaz A, Wu X, Rivas D, et al. Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro. J Cell Mol Med. 2010;14(4):982–991.
   PubMed Web of Science ®Google Scholar
• Singh L, Tyagi S, Myers D, et al. Good, bad, or ugly: the biological roles of bone marrow fat. Curr Osteoporos Rep. 2018 Apr;16(2):130–137.
   PubMed Web of Science ®Google Scholar
• Gunaratnam K, Vidal C, Boadle R, et al. Mechanisms of palmitate-induced cell death in human osteoblasts. Biol Open. 2013;2(12):1382–1389.
   PubMed Web of Science ®Google Scholar
• Gunaratnam K, Vidal C, Gimble JM, et al. Mechanisms of palmitate-induced lipotoxicity in human osteoblasts. Endocrinology. 2014 Jan;155(1):108–116.
   PubMed Web of Science ®Google Scholar
• Bermeo S, Al Saedi A, Vidal C, et al. Treatment with an inhibitor of fatty acid synthase attenuates bone loss in ovariectomized mice. Bone. 2019;122:114–122.
   PubMed Web of Science ®Google Scholar
• Roodman GD. Cell biology of the osteoclast. Exp Hematol. 1999;27(8):1229–1241.
   PubMed Web of Science ®Google Scholar
• Wada T, Nakashima T, Hiroshi N, et al. RANKL–RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006 Jan 01;12(1):17–25.
   PubMed Web of Science ®Google Scholar
• Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289(5484):1504–1508.
   PubMed Web of Science ®Google Scholar
• Cao JJ, Wronski TJ, Iwaniec U, et al. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. J Bone Miner Res. 2005;20(9):1659–1668.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Mishima H, Sakai S, et al. Gene expression analysis of major lineage-defining factors in human bone marrow cells: effect of aging, gender, and age-related disorders. J Orthop Res. 2008;26(7):910–917.
   PubMed Web of Science ®Google Scholar
• Oh KW, Rhee EJ, Lee WY, et al. Circulating osteoprotegerin and receptor activator of NF-κB ligand system are associated with bone metabolism in middle-aged males. Clin Endocrinol (Oxf). 2005;62(1):92–98.
   PubMed Web of Science ®Google Scholar
• Cao J, Venton L, Sakata T, et al. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. J Bone Miner Res. 2003;18(2):270–277.
   PubMed Web of Science ®Google Scholar
• Eastell R, Christiansen C, Grauer A, et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res. 2011;26(3):530–537.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–765.
   PubMed Web of Science ®Google Scholar
• Papapoulos S, Chapurlat R, Libanati C, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27(3):694–701.
   PubMed Web of Science ®Google Scholar
• Papapoulos S, Lippuner K, Roux C, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int. 2015;26(12):2773–2783.
   PubMed Web of Science ®Google Scholar
• Calvo A, Joensuu H, Sebastian M, et al. Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors. J Clin Oncol. 2018;36:3014.
   Google Scholar
• Cannarile MA, Weisser M, Jacob W, et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy [journal article]. J Immunother Cancer. 2017 July 18;5(1):53.
   PubMedGoogle Scholar
• Drake MT, Clarke BL, Khosla S, editors Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008 Sep;83(9):1032-1045..
   Google Scholar
• Vidal C, Bermeo S, Fatkin D, et al. Role of the nuclear envelope in the pathogenesis of age-related bone loss and osteoporosis. Bonekey Rep. 2012;1:5.
   PubMedGoogle Scholar
• Michael H, Harkonen PL, Vaananen HK, et al. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res. 2005 Dec;20(12):2224–2232.
   PubMed Web of Science ®Google Scholar
• Martín Millán M. The role of estrogen receptor in bone cells. Clin Rev Bone Miner Metab. 2015 June 01;13(2):105–112.
   Web of Science ®Google Scholar
• Nakamura T, Imai Y, Matsumoto T, et al. Estrogen prevents bone loss via estrogen receptor α and induction of Fas ligand in osteoclasts. Cell. 2007;130(5):811–823.
   PubMed Web of Science ®Google Scholar
• Krum SA, Miranda‐Carboni GA, Hauschka PV, et al. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. Embo J. 2008;27(3):535–545.
   PubMed Web of Science ®Google Scholar
• Miyaura C, Kusano K, Masuzawa T, et al. Endogenous bone‐resorbing factors in estrogen deficiency: cooperative effects of IL‐1 and IL‐6. J Bone Miner Res. 1995;10(9):1365–1373.
   PubMed Web of Science ®Google Scholar
• Jilka RL, Hangoc G, Girasole G, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. 1992;257(5066):88–91.
   PubMed Web of Science ®Google Scholar
• Arun B, Anthony M, Dunn B. The search for the ideal SERM. Expert Opin Pharmacother. 2002 Jun;3(6):681–691.
   PubMedGoogle Scholar
• Taylor HS. Designing the ideal selective estrogen receptor modulator–an achievable goal? Menopause (New York, NY). 2009 May -Jun;16(3):609–615.
   PubMed Web of Science ®Google Scholar
• Bonnelye E, Chabadel A, Saltel F, et al. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone. 2008;42(1):129–138.
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350(5):459–468.
   PubMed Web of Science ®Google Scholar
• Henriksen K, Leeming DJ, Byrjalsen I, et al. Osteoclasts prefer aged bone. Osteoporos Int. 2007 Jun 01;18(6):751–759.
   PubMed Web of Science ®Google Scholar
• Groessner-Schreiber B, Krukowski M, Hertweck D, et al. Osteoclast formation is related to bone matrix age. Calcif Tissue Int. 1991;48(5):335–340.
   PubMed Web of Science ®Google Scholar
• Groessner-Schreiber B, Krukowski M, Lyons C, et al. Osteoclast recruitment in response to human bone matrix is age related. Mech Ageing Dev. 1992;62(2):143–154.
   PubMed Web of Science ®Google Scholar
• Dejica VM, Mort JS, Laverty S, et al. Increased type II collagen cleavage by cathepsin K and collagenase activities with aging and osteoarthritis in human articular cartilage. Arthritis Res Ther. 2012 May 14;14(3):R113.
   PubMed Web of Science ®Google Scholar
• Dejica VM, Mort JS, Laverty S, et al. Cleavage of type II collagen by cathepsin K in human osteoarthritic cartilage. Am J Pathol. 2008;173(1):161–169.
   PubMed Web of Science ®Google Scholar
• Gauthier JY, Chauret N, Cromlish W, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008 Feb 01;18(3):923–928.
   PubMed Web of Science ®Google Scholar
• Chapurlat RD. Odanacatib: a review of its potential in the management of osteoporosis in postmenopausal women. Ther Adv Musculoskelet Dis. 2015;7(3):103–109.
   PubMed Web of Science ®Google Scholar
• Mullard A, Merck & Co.drops osteoporosis drug odanacatib. Nat Rev Drug Discov. 2016;15:669.
   Google Scholar
• Lu J, Wang M, Wang Z, et al. Advances in the discovery of cathepsin K inhibitors on bone resorption. J Enzyme Inhib Med Chem. 2018;33(1):890–904.
   PubMed Web of Science ®Google Scholar
• Kong -Y-Y, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999 Nov 01;402(6759):304–309.
   PubMed Web of Science ®Google Scholar
• Lam J, Takeshita S, Barker JE, et al. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000 dec 15;106(12):1481–1488.
   PubMed Web of Science ®Google Scholar
• Pacifici R, Rifas L, McCracken R, et al. The role of interleukin-1 in postmenopausal bone loss. Exp Gerontol. 1990;25(3–4):309–316.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Nakamura Y, Kato H. Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis. Ther Clin Risk Manag. 2018;14:453–459.
   PubMed Web of Science ®Google Scholar
• Ha H, Bok Kwak H, Woong Lee S, et al. Reactive oxygen species mediate RANK signaling in osteoclasts. Exp Cell Res. 2004 Dec 10;301(2):119–127.
   PubMed Web of Science ®Google Scholar
• Bax BE, Alam ASMT, Banerji B, et al. Stimulation of osteoclastic bone resorption by hydrogen peroxide. Biochem Biophys Res Commun. 1992 Mar 31;183(3):1153–1158.
   PubMed Web of Science ®Google Scholar
• He X, Andersson G, Lindgren U, et al. Resveratrol prevents RANKL-induced osteoclast differentiation of murine osteoclast progenitor RAW 264.7 cells through inhibition of ROS production. Biochem Biophys Res Commun. 2010 Oct 22;401(3):356–362.
   PubMed Web of Science ®Google Scholar
• Zeng H, Cao JJ, Combs GF. Selenium in bone health: roles in antioxidant protection and cell proliferation. Nutrients. 2013;5(1):97–110.
   PubMed Web of Science ®Google Scholar
• Moon H-J, Ko W-K, Han SW, et al. Antioxidants, like coenzyme Q10, selenite, and curcumin, inhibited osteoclast differentiation by suppressing reactive oxygen species generation. Biochem Biophys Res Commun. 2012 Feb 10;418(2):247–253.
   PubMed Web of Science ®Google Scholar
• Huynh N, VonMoss L, Smith D, et al. Characterization of regulatory extracellular vesicles from osteoclasts. J Dent Res. 2016;95(6):673–679.
   PubMed Web of Science ®Google Scholar
• Ikebuchi Y, Aoki S, Honma M, et al. Coupling of bone resorption and formation by RANKL reverse signalling. Nature. 2018 Sep 01;561(7722):195–200.
   PubMed Web of Science ®Google Scholar
• Tchkonia T, Zhu Y, Van Deursen J, et al. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest. 2013;123(3):966–972.
   PubMed Web of Science ®Google Scholar
• Davalli P, Mitic T, Caporali A, et al. ROS, cell senescence, and novel molecular mechanisms in aging and age-related diseases. Oxid Med Cell Longev. 2016;2016:3565127. .
   Google Scholar
• Khosla S, Farr JN, Kirkland JL. Inhibiting cellular senescence: a new therapeutic paradigm for age-related osteoporosis. J Clin Endocrinol Metab. 2018;103(4):1282–1290.
   PubMed Web of Science ®Google Scholar
• Farr JN, Fraser DG, Wang H, et al. Identification of senescent cells in the bone microenvironment. J Bone Miner Res. 2016;31(11):1920–1929.
   PubMed Web of Science ®Google Scholar
• Kim HN, Chang J, Shao L, et al. DNA damage and senescence in osteoprogenitors expressing Osx1 may cause their decrease with age. Aging Cell. 2017;16(4):693–703.
   PubMed Web of Science ®Google Scholar
• Farr JN, Xu M, Weivoda MM, et al. Targeting cellular senescence prevents age-related bone loss in mice. Nat Med. 2017 Aug 21; online 23:1072.
   PubMed Web of Science ®Google Scholar
• Feehan J, Nurgali K, Apostolopoulos V, et al. Circulating osteogenic precursor cells: building bone from blood. EBioMedicine. 2018;39:603–611.
   PubMed Web of Science ®Google Scholar
• Dalle Carbonare L, Valenti MT, Zanatta M, et al. Circulating mesenchymal stem cells with abnormal osteogenic differentiation in patients with osteoporosis. Arthritis Rheum. 2009 Nov;60(11):3356–3365.
   PubMedGoogle Scholar
• Pirro M, Leli C, Fabbriciani G, et al. Association between circulating osteoprogenitor cell numbers and bone mineral density in postmenopausal osteoporosis. Osteoporos Int. 2010 Feb;21(2):297–306.
   PubMed Web of Science ®Google Scholar
• Sui B, Hu C, Zhang X, et al. Allogeneic mesenchymal stem cell therapy promotes osteoblastogenesis and prevents glucocorticoid‐induced osteoporosis. Stem Cells Transl Med. 2016;5(9):1238–1246.
   PubMed Web of Science ®Google Scholar